Galectin Therapeutics Files 8-K
Ticker: GALT · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1133416
| Field | Detail |
|---|---|
| Company | Galectin Therapeutics INC (GALT) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, exhibits
Related Tickers: GALT
TL;DR
GALECTIN THERAPEUTICS (GALT) filed an 8-K on Jan 23, 2025, reporting financials & exhibits.
AI Summary
Galectin Therapeutics Inc. filed an 8-K on January 23, 2025, reporting on financial statements and exhibits. The company, formerly known as Pro Pharmaceuticals Inc., is incorporated in Nevada and headquartered in Norcross, Georgia.
Why It Matters
This filing provides an update on the company's financial reporting and exhibits, which can be important for investors to understand the company's current financial status and any new disclosures.
Risk Assessment
Risk Level: low — This is a routine filing reporting financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- Galectin Therapeutics Inc. (company) — Registrant
- Pro Pharmaceuticals Inc. (company) — Former company name
- January 23, 2025 (date) — Date of report
- Norcross, GA (location) — Principal executive office
- Nevada (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as of January 23, 2025.
What was Galectin Therapeutics Inc. formerly known as?
Galectin Therapeutics Inc. was formerly known as Pro Pharmaceuticals Inc.
In which state is Galectin Therapeutics Inc. incorporated?
Galectin Therapeutics Inc. is incorporated in Nevada.
Where is the principal executive office of Galectin Therapeutics Inc. located?
The principal executive office of Galectin Therapeutics Inc. is located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071.
What is the SEC file number for Galectin Therapeutics Inc.?
The SEC file number for Galectin Therapeutics Inc. is 001-31791.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-23 11:15:17
Key Financial Figures
- $0.001 — hange on which registered Common Stock $0.001 par value per share GALT The Nasdaq
Filing Documents
- ef20042040_8k.htm (8-K) — 28KB
- ef20042040_ex99-1.htm (EX-99.1) — 22KB
- 0001140361-25-001687.txt ( ) — 191KB
- galt-20250123.xsd (EX-101.SCH) — 4KB
- galt-20250123_lab.xml (EX-101.LAB) — 21KB
- galt-20250123_pre.xml (EX-101.PRE) — 16KB
- ef20042040_8k_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure. On January 23, 2025 , Galectin Therapeutics Inc. (the "Company) made a presentation after its Annual Meeting of Stockholders, a transcript of such is attached hereto as Exhibit 99.1. The information in this report is being furnished pursuant to this Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report . SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Transcript of presentation, January 23, 2025 - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: January 23, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 3 -